Vaszkuláris endoteliális növekedési faktor (VEGF) mint potenciális biomarker major depresszióval összefüggésben

Translated title of the contribution: Vascular endothelial growth factor (VEGF) as a potential biomarker in major depressive disorder

Eleméry Mónika, Kiss Szilvia, X. Gonda, P. Döme, J. Lazáry

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: There is growing evidence that vascular endothelial growth factor (VEGF) plays a crucial role in neurodevelopment and regeneration. Several data support that intact VEGF pathway is indispensable for therapeutic effect of antidepressants, any disruption of VEGF signaling can result treatment resistance. In our study we investigated the peripherial blood VEGF level before and 4-week after antidepressant treatment in patients with major depressive episode and we compared VEGF levels between responders and non-responders. Methods: We recruited 34 patients diagnosed with major depression disorder rom our department. Depressive symptoms were followed by the Montgomery Asberg Depression Scale. Level of VEGF was measured from peripheral plasma by ELISA technic. For comparisons we per­formed general linear models and Mann-Whitney U tests. Results: Baseline VEGF level was significantly higher in the non-responder subgroup compared to responders (p=0.017). In regression analyses the baseline and end-point VEGF levels were correlated with end-point MADRS (p=0.03; p=0.02, respectively). In our sample the higher baseline VEGF level was cor­related with 2.75 times greater chance for treatment resistance in non-responders compared to responders. Conclusion: Our results confirm the significant role of VEGF signaling in the pathomechanism of major depression disorder. These data suggest that high baseline VEGF level can be a predictor for lack of therapy response, thus VEGF can be regarded as a potential biomarker for treatment resistance in major depression disorder.

Original languageHungarian
Pages (from-to)183-188
Number of pages6
JournalNeuropsychopharmacologia Hungarica
Volume19
Issue number4
Publication statusPublished - Dec 1 2017

Fingerprint

Major Depressive Disorder
Vascular Endothelial Growth Factor A
Biomarkers
Depression
Antidepressive Agents
Therapeutics
Therapeutic Uses
Nonparametric Statistics
Regeneration
Linear Models
Enzyme-Linked Immunosorbent Assay
Regression Analysis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Clinical Neurology

Cite this

Vaszkuláris endoteliális növekedési faktor (VEGF) mint potenciális biomarker major depresszióval összefüggésben. / Mónika, Eleméry; Szilvia, Kiss; Gonda, X.; Döme, P.; Lazáry, J.

In: Neuropsychopharmacologia Hungarica, Vol. 19, No. 4, 01.12.2017, p. 183-188.

Research output: Contribution to journalArticle

@article{3946c95a15bf457e9a896f7716774688,
title = "Vaszkul{\'a}ris endoteli{\'a}lis n{\"o}veked{\'e}si faktor (VEGF) mint potenci{\'a}lis biomarker major depresszi{\'o}val {\"o}sszef{\"u}gg{\'e}sben",
abstract = "Background: There is growing evidence that vascular endothelial growth factor (VEGF) plays a crucial role in neurodevelopment and regeneration. Several data support that intact VEGF pathway is indispensable for therapeutic effect of antidepressants, any disruption of VEGF signaling can result treatment resistance. In our study we investigated the peripherial blood VEGF level before and 4-week after antidepressant treatment in patients with major depressive episode and we compared VEGF levels between responders and non-responders. Methods: We recruited 34 patients diagnosed with major depression disorder rom our department. Depressive symptoms were followed by the Montgomery Asberg Depression Scale. Level of VEGF was measured from peripheral plasma by ELISA technic. For comparisons we per­formed general linear models and Mann-Whitney U tests. Results: Baseline VEGF level was significantly higher in the non-responder subgroup compared to responders (p=0.017). In regression analyses the baseline and end-point VEGF levels were correlated with end-point MADRS (p=0.03; p=0.02, respectively). In our sample the higher baseline VEGF level was cor­related with 2.75 times greater chance for treatment resistance in non-responders compared to responders. Conclusion: Our results confirm the significant role of VEGF signaling in the pathomechanism of major depression disorder. These data suggest that high baseline VEGF level can be a predictor for lack of therapy response, thus VEGF can be regarded as a potential biomarker for treatment resistance in major depression disorder.",
keywords = "Affective disorder, Biomarker, Depression, Growth factor, Treatment resistant depression, VEGF",
author = "Elem{\'e}ry M{\'o}nika and Kiss Szilvia and X. Gonda and P. D{\"o}me and J. Laz{\'a}ry",
year = "2017",
month = "12",
day = "1",
language = "Hungarian",
volume = "19",
pages = "183--188",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "4",

}

TY - JOUR

T1 - Vaszkuláris endoteliális növekedési faktor (VEGF) mint potenciális biomarker major depresszióval összefüggésben

AU - Mónika, Eleméry

AU - Szilvia, Kiss

AU - Gonda, X.

AU - Döme, P.

AU - Lazáry, J.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: There is growing evidence that vascular endothelial growth factor (VEGF) plays a crucial role in neurodevelopment and regeneration. Several data support that intact VEGF pathway is indispensable for therapeutic effect of antidepressants, any disruption of VEGF signaling can result treatment resistance. In our study we investigated the peripherial blood VEGF level before and 4-week after antidepressant treatment in patients with major depressive episode and we compared VEGF levels between responders and non-responders. Methods: We recruited 34 patients diagnosed with major depression disorder rom our department. Depressive symptoms were followed by the Montgomery Asberg Depression Scale. Level of VEGF was measured from peripheral plasma by ELISA technic. For comparisons we per­formed general linear models and Mann-Whitney U tests. Results: Baseline VEGF level was significantly higher in the non-responder subgroup compared to responders (p=0.017). In regression analyses the baseline and end-point VEGF levels were correlated with end-point MADRS (p=0.03; p=0.02, respectively). In our sample the higher baseline VEGF level was cor­related with 2.75 times greater chance for treatment resistance in non-responders compared to responders. Conclusion: Our results confirm the significant role of VEGF signaling in the pathomechanism of major depression disorder. These data suggest that high baseline VEGF level can be a predictor for lack of therapy response, thus VEGF can be regarded as a potential biomarker for treatment resistance in major depression disorder.

AB - Background: There is growing evidence that vascular endothelial growth factor (VEGF) plays a crucial role in neurodevelopment and regeneration. Several data support that intact VEGF pathway is indispensable for therapeutic effect of antidepressants, any disruption of VEGF signaling can result treatment resistance. In our study we investigated the peripherial blood VEGF level before and 4-week after antidepressant treatment in patients with major depressive episode and we compared VEGF levels between responders and non-responders. Methods: We recruited 34 patients diagnosed with major depression disorder rom our department. Depressive symptoms were followed by the Montgomery Asberg Depression Scale. Level of VEGF was measured from peripheral plasma by ELISA technic. For comparisons we per­formed general linear models and Mann-Whitney U tests. Results: Baseline VEGF level was significantly higher in the non-responder subgroup compared to responders (p=0.017). In regression analyses the baseline and end-point VEGF levels were correlated with end-point MADRS (p=0.03; p=0.02, respectively). In our sample the higher baseline VEGF level was cor­related with 2.75 times greater chance for treatment resistance in non-responders compared to responders. Conclusion: Our results confirm the significant role of VEGF signaling in the pathomechanism of major depression disorder. These data suggest that high baseline VEGF level can be a predictor for lack of therapy response, thus VEGF can be regarded as a potential biomarker for treatment resistance in major depression disorder.

KW - Affective disorder

KW - Biomarker

KW - Depression

KW - Growth factor

KW - Treatment resistant depression

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85041122419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041122419&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 183

EP - 188

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 4

ER -